The global epidemics of diabetes in the 21st century: Current situation and perspectives

European Journal of Preventive Cardiology - Tập 26 Số 2_suppl - Trang 7-14 - 2019
Eberhard Standl1, Kamlesh Khunti2, Parounak Zelveian3, Oliver Schnell1
1Forschergruppe Diabetes eV at Munich Helmholtz Centre, Germany
2Diabetes Research Centre, University of Leicester, UK
3Department of Cardiology, Zealand University Hospital, Denmark

Tóm tắt

Diabetes is on the rise worldwide, with a global prevalence in adults in 2017 being 8.8% of the world population, with the anticipation of a further increase to 9.9% by 2045. In total numbers, this reflects a population of 424.9 million people with diabetes worldwide in 2017, with an estimate of a 48% increase to 628.6 million people by 2045. Depending on age, global diabetes prevalence is about 5%, 10%, 15% and close to 20%, respectively, for the age groups 35–39, 45–49, 55–59 and 65–69 years. On a global scale, diabetes hits particularly ‘middle aged’ people between 40 and 59 years, which causes serious economic and social implications. Furthermore, diabetes affects especially low and middle income countries, as 77% of all people with diabetes worldwide live in those countries. In addition to overt diabetes, an estimated 352.1 million people worldwide are at risk of diabetes, i.e. have defined pre-diabetes, a figure which is anticipated to rise to 531.6 million by 2045. Some 70–75% of all patients with established coronary artery disease, e.g. with acute myocardial infarction, show concomitant diabetes or abnormal glucose regulation, i.e. close to 50% have overt diabetes, with as many as 20% of those being undiagnosed and another 25% having pre-diabetes.

Từ khóa


Tài liệu tham khảo

Rydén L, 2007, Eur Heart J, 28, 88, 10.1093/eurheartj/ehm124

Cosentino F, Eur Heart J

10.1007/s00125-018-4711-2

10.1016/j.jacc.2019.03.009

World Health Organization, 2006, Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation

10.2337/dc17-S005

10.1016/S0140-6736(16)00618-8

10.1056/NEJMoa1008862

10.1253/circj.CJ-14-0850

10.1016/S0140-6736(16)30054-X

10.1016/S0140-6736(17)32129-3

10.1161/CIRCULATIONAHA.115.018585

10.1001/jama.2017.7596

10.1056/NEJMoa1608664

10.1016/S0140-6736(17)31371-5

10.1016/S0140-6736(17)32461-3

10.1016/j.ehj.2004.07.027

Gitt A, 2013, J Am Coll Cardiol, 61

10.1093/eurheartj/ehv008

10.1161/CIRCHEARTFAILURE.115.002560

10.1177/2047487318825350

10.1177/2047487317754011

10.1177/2047487318757553

10.1093/eurheartj/ehy320

10.1016/j.diabres.2010.06.008

10.1007/BF02374493

10.2337/diacare.25.7.1129

10.1007/s00125-017-4478-x

10.1016/S0140-6736(11)61215-4

10.1016/S0140-6736(18)31506-X

10.2337/dc17-1091

10.1016/S0140-6736(98)12131-1

10.1007/s001250051211

10.2337/dc15-0369

10.1001/archinte.159.16.1873

10.2337/dc17-1962

10.1016/S2213-8587(17)30097-9